Cargando…

Cytotoxic T-cell precursor frequencies to HER-2 (369 – 377) in patients with HER-2/neu-positive epithelial tumours

HER-2/neu oncoprotein contains several major histocompatibility complex class I-restricted epitopes, which are recognised by cytotoxic T lymphocyte (CTL) on autologous tumours and therefore can be used in immune-based cancer therapies. Of these, the most extensively studied is HER-2(9(369)). In the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sotiropoulou, P A, Perez, S A, Iliopoulou, E G, Missitzis, I, Voelter, V, Echner, H, Baxevanis, C N, Papamichail, M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Molecular and Cellular Pathology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376937/ https://www.ncbi.nlm.nih.gov/pubmed/12966425 http://dx.doi.org/10.1038/sj.bjc.6601244

Ejemplares similares

HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder
por: Latif, Z, et al.
Publicado: (2003)

Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients
por: Ady, N, et al.
Publicado: (2004)

Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas
por: Hirsch, F R, et al.
Publicado: (2002)

Clinical significance of Caveolin-1, Caveolin-2 and HER2/neu mRNA expression in human breast cancer
por: Sagara, Y, et al.
Publicado: (2004)

Review of the Role of HER2/neu in Colorectal Carcinomas
por: Achalla, Lakshmi Sai Vijay, et al.
Publicado: (2022)

Peptide HER2(776–788) represents a naturally processed broad MHC class II-restricted T cell epitope
por: Sotiriadou, R, et al.
Publicado: (2001)

Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2004)

HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review
por: Carlsson, J, et al.
Publicado: (2004)

Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo
por: Gritzapis, A D, et al.
Publicado: (2005)

HER2/neu testing in primary colorectal carcinoma
por: Ingold Heppner, B, et al.
Publicado: (2014)

Prognostic significance of EGFR and Her-2 in oral cavity cancer in betel quid prevalent area cancer prognosis
por: Chen, I-H, et al.
Publicado: (2003)

Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide
por: Voutsas, Ioannis F., et al.
Publicado: (2016)

Evaluation of HER2Neu Status in Periampullary Cancers in Tertiary Care Centre in Northern India: A Three-Year Retrospective Study
por: Qayoom, Sumaira, et al.
Publicado: (2023)

Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells
por: Gritzapis, A D, et al.
Publicado: (2003)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma
por: Mimura, K, et al.
Publicado: (2005)

The mannosylated extracellular domain of Her2/neu produced in P. pastoris induces protective antitumor immunity
por: Dimitriadis, Alexios, et al.
Publicado: (2009)

Luminal B, Human Epidermal Growth Factor Receptor 2 (HER2/neu), and Triple-Negative Breast Cancers Associated With a Better Chemotherapy Response Than Luminal A Breast Cancers in Postneoadjuvant Settings
por: Hashmi, Atif A, et al.
Publicado: (2023)

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
por: DiGiovanna, M. P., et al.
Publicado: (1996)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

The Clinical Importance of the Heterogeneity of HER2 neu
por: Davila, Enrique, et al.
Publicado: (2010)

In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway
por: Pils, D, et al.
Publicado: (2007)

UDP-Gal: βGlcNAc β1, 3-galactosyltransferase, polypeptide 3 (GALT3) is a tumour antigen recognised by HLA-A2-restricted cytotoxic T lymphocytes from patients with brain tumour
por: Tsuda, N, et al.
Publicado: (2002)

Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis
por: de Graeff, P, et al.
Publicado: (2009)

HER 2/neu protein expression in colorectal cancer
por: Schuell, B, et al.
Publicado: (2006)

HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
por: Moelans, Cathy B., et al.
Publicado: (2010)

Anti-HER2/Neu passive-aggressive immunotherapy
por: Mortenson, Eric D, et al.
Publicado: (2014)

Overexpression of Her-2 in Biopsy-Proven Urothelial Carcinoma Patients From Pakistan
por: Chughtai, Anila, et al.
Publicado: (2022)

Correlation of HER2 With p53 and p63 in Urothelial Bladder Carcinoma
por: Ponnaboina, Divya Madhuri, et al.
Publicado: (2023)

Correlation of HER2/neu antibody response to clinical response in a Phase II trial of the ae37+gm-csf her2 peptide vaccine
por: Greene, Julia, et al.
Publicado: (2014)

Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer
por: Ahmed, N, et al.
Publicado: (2004)

Detection and molecular characterisation of thyroid cancer precursor lesions in a specific subset of Hashimoto's thyroiditis
por: Gasbarri, A, et al.
Publicado: (2004)

Expression of Septin 2 and Her2/neu in Colorectal Cancer
por: Hanbuli, Hala M. El, et al.
Publicado: (2021)

Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition
por: Correa, Isabel, et al.
Publicado: (2001)

S100A6 (Calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursors
por: Rehman, I, et al.
Publicado: (2004)

Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8(+) T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
por: Chen, Y, et al.
Publicado: (2011)

Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
por: Brodowicz, T, et al.
Publicado: (2001)

Primary screening for cervical cancer precursors by the combined use of liquid-based cytology, computer-assisted cytology and HPV DNA testing
por: Vassilakos, P, et al.
Publicado: (2002)

Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications
por: Ferrandina, G, et al.
Publicado: (2002)

HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ
por: Rakovitch, E, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ngpbafe7nf075bn9fn0n4trkfd